Interestingly, mice treated with BMS309403 exhibited reduced symptoms of diabetes, atherosclerosis and mammary tumor growth [16, 34], suggesting that targeting FABP4 with small-molecular inhibitors might represent a promising approach for treating obesity-associated diseases. Here, FABP4 is linked to breast cancer.